SGLT2 Inhibitor, Canagliflozin, Attenuates Myocardial Infarction in the Diabetic and Nondiabetic Heart (JACC: Basic to Translational Science February 2019) is organized by American College of Cardiology (ACC).

Important Dates:
Date of Release: February 25, 2019
Term of Approval/Date of CME/MOC/ECME Expiration: February 25, 2020

Target Audience:
JACC Journal CME/MOC is intended for physicians who treat patients with cardiovascular disease.

Credit Offered: 
• CME:1.0
• COP:1.0
• ECME:1.0
• MOC:1.0

Recent landmark cardiovascular outcome trials (EMPA-REG OUTCOME [Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients] and CANVAS [Canagliflozin Cardiovascular Assessment Study]) have revealed an unexpected cardiovascular mortality benefit from sodium/glucose cotransporter 2 (SGLT2) inhibition in patients with diabetes mellitus with high cardiovascular risk. We hypothesized that some of this benefit is derived through attenuation of ischemia/reperfusion injury, independent of glycemic status.

Learner Objectives:
After reading this article the reader should be able to:
• Discuss the effects of treatment with canagliflozin on myocardial infarct size among Zucker Diabetic Fatty (ZDF) rats with diabetes mellitus and Zucker Lean (ZL) rats without diabetes mellitus.
• Examine the guideline recommendations for prevention of acute myocardial infarction in patients with diabetes mellitus.
• Define the potential applications of canagliflozin on cardiovascular health among people with or at risk of cardiovascular disease.

Additional details will be posted as soon as they are available.

Intended Audience


Activity Payment Details

Activity Fee : Free

Rate this CME (Min 1 - Max 5)

Fee and expenses:
CME credits:
Program contents:
Write Your Review

Reviews Given by Professionals

No Reviews available. Be the first to write a review.

Privacy Policy

Read eMedEvents Privacy Policy


American College of Cardiology (ACC)

View Organizer Details


800-253-4636 x5603, 202-375-6000 x5603